GeoVax Labs Files 8-K: Corporate Updates
Ticker: GOVX · Form: 8-K · Filed: Oct 15, 2024 · CIK: 832489
Sentiment: neutral
Topics: corporate-filing, 8-K, pharmaceuticals
Related Tickers: GOVX
TL;DR
GeoVax Labs filed an 8-K on Oct 15, 2024, with corporate and financial updates.
AI Summary
GeoVax Labs, Inc. filed an 8-K on October 15, 2024, reporting other events and financial statements. The filing details the company's incorporation in Delaware, its fiscal year end of December 31, and its primary business in pharmaceutical preparations. The report also lists previous company names and dates of name changes.
Why It Matters
This 8-K filing provides essential corporate information and updates for GeoVax Labs, Inc., which is crucial for investors and stakeholders to understand the company's structure and reporting status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- GeoVax Labs, Inc. (company) — Registrant
- October 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary business of GeoVax Labs, Inc. according to this filing?
GeoVax Labs, Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 15, 2024.
In which state was GeoVax Labs, Inc. incorporated?
GeoVax Labs, Inc. was incorporated in Delaware.
What is the Commission File Number for GeoVax Labs, Inc.?
The Commission File Number for GeoVax Labs, Inc. is 001-39563.
What are the previous names of GeoVax Labs, Inc. mentioned in the filing?
Previous names mentioned include DAUPHIN TECHNOLOGY INC (name change date 19940826), SUCCESSO INC (name change date 19910410), and Geovax Labs, Inc. (name change date 20061002).
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 9.1 · Accepted 2024-10-15 16:45:13
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share GOVX The Nasdaq Capital M
- $4,486,846 — artners, dated September 25, 2024, from $4,486,846 to $30,000,000. A copy of the legal opi
- $30,000,000 — September 25, 2024, from $4,486,846 to $30,000,000. A copy of the legal opinion as to the
Filing Documents
- govx20241014_8k.htm (8-K) — 28KB
- ex_732587.htm (EX-5.1) — 15KB
- w01.jpg (GRAPHIC) — 3KB
- w02.jpg (GRAPHIC) — 11KB
- w03.jpg (GRAPHIC) — 9KB
- w04.jpg (GRAPHIC) — 3KB
- 0001437749-24-031266.txt ( ) — 229KB
- govx-20241015.xsd (EX-101.SCH) — 4KB
- govx-20241015_def.xml (EX-101.DEF) — 13KB
- govx-20241015_lab.xml (EX-101.LAB) — 17KB
- govx-20241015_pre.xml (EX-101.PRE) — 13KB
- govx20241014_8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events. On October 15, 2024, GeoVax Labs, Inc. (the "Company") increased the maximum aggregate offering price of the shares issuable under its Sales Agreement (the "Sales Agreement") with A.G.P./Alliance Global Partners, dated September 25, 2024, from $4,486,846 to $30,000,000. A copy of the legal opinion as to the legality of the shares issuable under the Sales Agreement is filed as Exhibit 5.1 attached hereto.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description. 5.1 Opinion of Womble Bond Dickinson (US) LLP. 23.1 Consent of Womble Bond Dickinson (US) LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. GeoVax Labs, Inc. Date: October 15, 2024 By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer